Prevalence of maternal and obstetrical risk factors of prematurity by age group.

<p>Prevalence of maternal and obstetrical risk factors of prematurity by age group.</p

Value of adjusted ORs to predict preterm delivery before 32 weeks and 37 weeks.

<p>Value of adjusted ORs to predict preterm delivery before 32 weeks and 37 weeks.</p

Flow chart.

<p>Flow chart.</p

Risks of all preterm delivery (spontaneous and iatrogenic) before 37 weeks and adjusted odds ratio according to maternal age categories.

<p>Risks of all preterm delivery (spontaneous and iatrogenic) before 37 weeks and adjusted odds ratio according to maternal age categories.</p

Maternal, pregnancy and newborn characteristics in gestational hypertensive versus non-hypertensive twin pregnancies in the study population, U.S. 1995–2000.

<p>Data presented are n (%). P values are from Chi-square tests for differences between diabetic and non-diabetic pregnancies. *SGA = Small-for-gestational-age <10^th percentile, LGA = large-for-gestational-age >90^th percentile, according to birth weight percentiles in non-malformation births to non-smoking mothers in the study cohort.</p>c<p> One or more of the following conditions: diabetes, heart disease, acute or chronic lung disease, renal disease, genital herpes and RH sensitization.</p>t<p> There were significant numbers of missing value (>10%) for smoking (n = 49494 mothers) (17.8%) and mode of delivery (101368 mothers) (36.4%). The numbers of missing for other variables were: race 0, marital status 705 (0.3%) mothers, age 0, education 3389 (1.2%) mothers, parity 12 (0.0%), other maternal illness 20721 (7.4%) mothers, preterm birth 0, low birth weight, SGA or LGA 8615 (1.5%) newborns. The rates for smoking and caesarean section, SGA, et al. are based on births with non-missing information.</p

Stillbirth in gestational hypertensive versus non-hypertensive twin pregnancies, U.S. matched multiple birth data 1995–2000.

<p>HR = Hazard ratio; CI =  confidence interval.</p><p>*Hazard ratios adjusted for maternal race, marital status, age, education, parity, smoking, other maternal major illnesses, fetal sex, mode of delivery and twin-cluster level dependence in Cox regression models.</p><p>**There were a significant number of stillbirths with missing birth weights.</p>t<p> Gestational age group-specific mortality rates and hazard ratios were calculated using the number of foetuses at risk and the number of stillbirths in the time interval specified.</p

Survival probabilities during the perinatal period (from 20 weeks gestation to 4 weeks postpartum) in gestational hypertensive vs. non-hypertensive twin pregnancies.

<p>Survival probabilities during the perinatal period (from 20 weeks gestation to 4 weeks postpartum) in gestational hypertensive vs. non-hypertensive twin pregnancies.</p

Perinatal mortality in gestational hypertensive versus non-hypertensive twin pregnancies, U.S. matched multiple birth data 1995–2000.

<p>HR = Hazard ratio; CI =  confidence interval.</p><p>*Hazard ratios adjusted for maternal race, marital status, age, education, parity, smoking, other maternal major illnesses, fetal sex, mode of delivery and twin-cluster level dependence in Cox regression models.</p><p>**There were a significant number of perinatal deaths with missing birth weights.</p>t<p> Gestational age group-specific mortality rates and hazard ratios were calculated using the number of foetuses at risk and the number of perinatal deaths in the time interval specified.</p

Halting the Canadian STRIDER randomised controlled trial of sildenafil for severe, early-onset fetal growth restriction: ethical, methodological, and pragmatic considerations

Objectives To determine the efficacy and safety of sildenafil citrate to improve outcomes in pregnancies complicated by early-onset, dismal prognosis, fetal growth restriction (FGR). Eligibility: women ≥ 18 years, singleton, 18 + 0–27 + 6 weeks’ gestation, estimated fetal weight  Results Between May 2017 and June 2018, 21 (90 planned) women were randomised [10 sildenafil; 11 placebo (1 withdrawal)]. Baseline characteristics, PLGF levels, maternal and perinatal outcomes, and adverse events did not differ. Delivery GA: 26 + 6 weeks (sildenafil) vs 29 + 2 weeks (placebo); p = 0.200. Data will contribute to an individual participant data meta-analysis.</p